After Ariad v. Lilly: Implications and Best Practices

(A Steptoe-Sponsored Event)
April 27, 2010
2:30 p.m. - 4:00 p.m. EDT

If you would like to receive a recording of this webinar, please contact Steptoe Events.

Join Steptoe’s Intellectual Property practice for a complimentary webinar featuring:  

  • Guy Donatiello, Vice President, Intellectual Property at Endo Pharmaceuticals, Chadds Ford, PA
  • Thomas P. McBride, Senior Counsel, Intellectual Property at Monsanto Company, St. Louis, MO
  • Kevin H. Rhodes, President and Chief Intellectual Property Counsel at 3M Innovative Properties Company, St. Paul, MN
  • Marian Underweiser, Intellectual Property Law Counsel at IBM Corporation, Armonk, NY
  • Moderator: Roger W. Parkhurst, Senior Partner, Steptoe & Johnson LLP, Washington DC, and Past-President, AIPLA

Date: Tuesday, April 27, 2010

2:30 p.m. - 4:00 p.m. EDT

This deeply experienced panel of US patent experts from a spectrum of interested industries will discuss the impact of the Federal Circuit’s en banc opinion in Ariad  Corp. et al v. Eli Lilly and Co., decided March 22, 2010. Likely topics of discussion include how the Ariad opinion may affect:

  • US patent specifications and claim drafting;
  • PTO examination of US patent applications;
  • Claim construction and validity analysis of issued US patents;
  • Post-Ariad attacks on and defenses of the scope and validity of US patents in US courts and the USITC; and
  • Possible further judicial development of post-Ariad practices.

Since the written description and enablement requirements of 35 USC § 112, first paragraph, affect all US patent applications and issued patents, this timely discussion should be of interest to all US patent owners and practitioners.

For more information about the webinar, please e-mail

Please visit for more information about Steptoe's Intellectual Property practice.